Satellos Bioscience Inc.
Research Satellos Bioscience Inc. (MSCL) on Bullrun: market cap CAD 286.63M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMSCL
- ExchangeTO
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCAD
- Market capCAD 286.63M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 9.77M
- Free cash flow-USD 9.59M
Valuation Snapshot
latest market cap is CAD 286.63M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 24.87M | -USD 23.60M | n/a | n/a | USD 9.80M | n/a | USD 27.78M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | CAD 286.63M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CAD.
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Satellos Bioscience Inc.'s market cap?
Satellos Bioscience Inc.'s market capitalization is CAD 286.63M.
What does Satellos Bioscience Inc. do?
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease.